Twenty-four patients with endometrial carcinoma received tamoxifen (Nolvadex) for 7 days. Before and after administration, circulating hormones (estradiol, testosterone, progesterone, gonadotropins FSH and LH) were evaluated. Estrogen (ER) and progesterone receptors (PgR) in neoplastic tissue were also assayed. Our results show a net increase in PgR content and a signicant decrease in gonadotropin levels after the treatment. The authors suggest that clinical trials be conducted using tamoxifen and progestins for adjuvant therapy after surgery of endometrial carcinoma and for the therapeutic approach of advanced carcinoma.
Get full access to this article
View all access options for this article.
References
1.
AntunesC.M.F., StolleyP.D., RosensheinN.B., TonasciaJ.A.: Endometrial cancer and estrogen use: Report of a large case-control study.N. Engl. J. Med., 300: 9–16, 1979.
2.
BonteJ., DecosterJ.M., IdeP., WynatsP., BilletG.: Hormone prophylaxis and hormone therapy in the treatment of endometrial endocarcinoma by means of medroxyprogesterone acetate.Gynecol. Oncol., 6: 60–75, 1978.
3.
EhrlichC.E., YoungP.C.M.: Prediction of hormone sensitivity in endometrial carcinoma.Rev. Endocrine-Related Cancer, 6: 13–19, 1980.
4.
GurpideE.: Hormone receptors in endometrial cancer.Cancer, 48: 638–641, 1981.
5.
IsmailA.A.A., NiswenderG.D., MidgleyA.R.Jr.: Radioimmunoassay of testosterone without chromatography.J. Clin. Endocrinol., 34: 177–184, 1972
6.
JänneO., KaupillaA., KontulaK., SyrjäläP., VierikkoP., VihkoR.: Female sex steroid receptors in human endometrial hyperplasia and carcinoma.Int. J. Cancer, 24: 545–552, 1979.
7.
KelleyR.M., BakerW.T.: Progestational agents in the treatment of carcinoma of the endometrium.N. Engl. J. Med., 264: 216–225, 1961.
8.
KokkoE., JänneO., KaupillaA., VihkoR.: Effects of tamoxifen, medroxyprogesterone acetate and their combination on human endometrial estrogen and progestin receptor concentration, 17-beta-hydroxysteroid dehydrogenase activity and serum hormone concentration.Am. J. Obstet. Gynecol., 143: 382–388, 1982.
9.
LauritzenC.: A retrospective study concerning postmenopausal estrogen therapy and endometrial carcinoma. Presented at the Second International Meeting of Endometrial Cancer and Related Topics, London, March 30–31, 1977.
10.
McGuireW.L.: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy.Sem. Oncol., 5: 428–433, 1978.
11.
MidgleyA.R.Jr.: Radioimmunoassay for human follicle stimulating hormone.J. Endocrinol. Metab., 27: 295–298, 1967.
12.
MidgleyA.R.Jr.: Radioimmunoassay: A method for human chorionic gonadotropin and human luteinizing hormone.Endocrinology, 79: 10–18, 1966.
13.
MortelR., LevyC., WolffJ.P., NicolasJ.C., RobelP., BaulieuE.E.: Female sex steroid receptors in postmenopausal endometrial carcinoma and bio-chemical response to an antiestrogen.Cancer Res., 41: 1140–1147, 1981.
14.
NeumannovaM., KauppilaA., VihkoR.: Cytosol and nuclear estrogen and progestin receptors and 17-beta-hydroxysteroid activity in normal and carcinomatous endometrium.Obstet. Gynecol., 61: 181–188, 1983.
15.
RatcliffeW.A., CorrieJ.E.T., DolzielA.H., Mac PhersonJ.S.: Direct 125I-radioligand assays for serum progesterone compared with assay involving extraction of serum.Clin. Chem., 28: 1314–1318, 1982.
16.
RicciG., SacconiL., MagriniO.: Radioimmunoassay of 17-beta-estradiol.Biodata Bull., 1: 9–15, 1976.
17.
RobelP., MortelR., LevyC., BaulieuE.E.: Steroid receptors in postmenopausal endometrial carcinoma: The potential of a dynamic test using tamoxifen.Rev. Endocrine-Related Cancer, 9: 271–280, 1981.
18.
ScatchardG.: The attraction of proteins for small molecules and ions.Ann. N.Y. Acad. Sci., 51: 660–663, 1949.
